Integrating irinotecan in standard chemotherapy: A novel dose-density combination for high-risk pediatric sarcomas.

Gianni Bisogno Andrea C FerrariArianna TagarelliSilvia SorbaraStefano ChiaravalliElena PoliGiovanni ScarzelloFederica De CortiMichela CasanovaMaria Carmen Affinita

Published in: Pediatric blood & cancer (2021)

A dose-density strategy combining irinotecan with standard chemotherapy is feasible. This approach will be investigated in the next trial coordinated by the European pediatric Soft tissue sarcoma Study Group.

Keyphrases

locally advanced
clinical trial
phase iii
squamous cell carcinoma
atomic force microscopy
randomized controlled trial
childhood cancer
high speed